Diagnostics company LANGaware has secured $2 million in seed funding to advance its AI platform for detection of cognitive and mental health conditions. The funding was led by Eleven Ventures, along with strategic investors from the healthcare industry and existing investor Metavallon VC.
LANGaware aims to enable early detection and tailored support for individuals at risk of or affected by neurodegenerative and psychiatric disorders, reducing misdiagnoses and unnecessary treatments. The company’s platform analyzes language, voice, and speech through digital biomarkers to predict and monitor cognitive and mental health conditions, such as mild cognitive impairment, Alzheimer’s and depression.
Dr Vassiliki Rentoumi, the founder and CEO of LANGaware, is a distinguished researcher in the fields of natural language processing and computational linguistics.
“This investment propels us forward, unlocking the potential to revolutionize healthcare systems by unleashing the full power of AI,” said Rentoumi. “By harnessing the power of technology, we aim to alleviate the strain on overburdened healthcare systems, while driving down costs and fostering a future where accessible, high-quality healthcare is a fundamental right for all.”
The funding will be used to accelerate LANGaware’s AI capabilities by strengthening its technology development and product teams. The funds will also support extending the platform’s use in virtual care platforms and health systems in the United States.
“Through its speech-based flagging system for early detection, LANGaware is an example of how even the most pressing issues in healthcare can be addressed through the power of science and technology,” Valeri Petrov, Partner at Eleven Ventures. “We are excited to support LANGaware in their mission to impact millions of lives and contribute to a more efficient and timely treatment.”
LANGaware says its technology has been rigorously tested in clinical and virtual care settings in the United States and Greece.